Home Search Abstracts Browse Oral Sessions Browse Poster Sessions

 

Session 42-Oral Abstracts
Treatment Outcomes in Women and Children
Friday, 9:30 am-12 noon; Room 2005
9:30 am      152 Effect of Hormonal Contraceptive Use on Time to AIDS or Death in Female HIV Seroconverters in Rakai, Uganda
Chelsea Polis*1, M Wawer1, D Serwadda2, F Nalugoda3, N Kiwanuka3, J Kagaayi3, M Chen1, H Brahmbhatt1, and R Gray1
1Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US; 2Inst of Publ Hlth, Makerere Univ, Kampala, Uganda; and 3Rakai Hlth Sci Prgm, Uganda Virus Res Inst, Entebbe
9:45 am  153LB Efficacy of ART with NVP+TDF/FTC vs LPV/r+TDF/FTC among Antiretroviral-naïve Women in Africa: OCTANE Trial 2/ACTG A5208
James McIntyre*1, M Hughes2, J Mellors3, Y Zheng2, J Hakim4, A Asmelash5, F Conradie6, R Schooley7, J Currier8, S Lockman2,5,9, and A5208/OCTANE Study Team
1Chris Hani Baragwanath Hosp, Johannesburg, South Africa; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Univ of Pittsburgh Med Ctr, PA, US; 4Univ of Zimbabwe, Harare; 5Botswana-Harvard AIDS Inst, Gaborone; 6Univ of the Witwatersrand, Johannesburg, South Africa; 7Univ of California, San Diego, US; 8Univ of California, Los Angeles, US; and 9Brigham and Women`s Hosp, Boston, MA, US
10:00 am      154 NNRTI-resistant Variants Detected by Allele-specific PCR Predict Outcome of NVP-containing ART in Women with Prior Exposure to sdNVP: Results from the OCTANE/A5208 Study
Valerie Boltz*1, Y Zheng2, S Lockman3, F Hong4, E Halvas4, J McIntyre5, J Currier6, M Hughes2, J Coffin7, J Mellors4, and A5208 OCTANE Study Team
1HIV Drug Resistance Prgm, NCI-Frederick, MD, US; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Brigham and Women’s Hosp, Boston, MA, US; 4Univ of Pittsburgh, PA, US; 5Univ of the Witwatersrand, Johannesburg, South Africa; 6Univ of California, Los Angeles, US; and 7Tufts Univ, Boston, MA, US
10:15 am      155 Co-factors for HIV Incidence during Pregnancy and the Postpartum Period
John Kinuthia*1, J Kiarie1, C Farquhar2, B Richardson2, R Nduati3, D Mbori-Ngacha3, and G John-Stewart2
1Kenyatta Natl Hosp, Nairobi, Kenya; 2Univ of Washington, Seattle, US; and 3Univ of Nairobi, Kenya
10:30 am      156 Repeat HIV Testing in Labor and Delivery as a Standard of Care Increases ARV Provision for Women Who Seroconvert during Pregnancy
Mary Pat Kieffer*1, H Hoffman2, B Nlabhatsi3, M Mahdi1, K Kudiabor1, C Wilfert4, V Lukhele5, A Nakato-Waligo1, and N Maseko3
1Elizabeth Glaser Pediatric AIDS Fndn, Swaziland; 2George Washington Univ, Washington, DC, US; 3Ministry of Hlth, Swaziland; 4Elizabeth Glaser Pediatric AIDS Fndn, Washington, DC, US; and 5Swaziland Natl AIDS Prgm
10:45 am      157 12-Month Follow-up of the SWEN Randomized Controlled Trials: Differential Impact of Infant Extended-dose NVP by CD4 Count on Prevention of HIV Transmission via Breastfeeding, and Infant Mortality
Abubaker Bedri and SWEN Study Team
Faculty of Med, Addis Ababa Univ, Ethiopia
11:00 am  158LB National Scale-up of Early Infant Diagnostic Testing for HIV in Uganda
Charles Kiyaga*1, S Tripathi2, I McConnell3, A Kekitinwa4, R Gass2, A Chatterjee2, R Oketch5, R Ekpini2, C Luo2, and Z Akol1
1AIDS Control Prgm, Ministry of Hlth Uganda, Kampala; 2UNICEF, New York, NY, US; 3Clinton Fndn, Kampala, Uganda; 4Baylor Uganda, Kampala; and 5UNICEF, Kampala, Uganda
11:15 am      159 Plasma Frequencies of Nevirapine Resistance Influence Virologic Responses to Nevirapine Maintenance Therapy in Single-dose Exposed HIV-infected Children Initially Treated with Lopinavir HAART
Anitha Moorthy*1, L Kuhn2, A Coovadia3, T Meyers3, G Sherman3, W-Y Tsai2, R Strehlau3, Y Chen4, E Abrams2, D Persaud4, and NEVEREST-2 Study Team
1Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US; 2Columbia Univ, Mailman Sch of Publ Hlth, New York, NY, US; 3Univ of the Witwatersrand, Johannesburg, South Africa; and 4Johns Hopkins Univ Sch of Med, Baltimore, MD, US
11:30 am      160 Treatment Outcomes among HIV-infected Infants and Young Children following Modifications to Protease Inhibitor-based Therapy Due to TBTreatment
M Moodley1, C Reitz2, Lee Fairlie*1,3, H Moultrie1,3, A Coovadia3,4, L Kuhn5, and T Meyers1,3
1Chris Hani Baragwanath Hosp, Johannesburg, South Africa; 2Gertrude H Sergievsky Ctr, Columbia Univ, Mailman Sch of Publ Hlth, New York, NY, US; 3Univ of the Witwatersrand, Johannesburg, South Africa; 4Coronation Women and Children Hosp, Johannesburg, South Africa; and 5Intl Ctr for AIDS Care and Treatment Prgms, Columbia Univ, Mailman Sch of Publ Hlth and Coll of Physicians and Surgeons, New York, NY, US
11:45 am  161LB Interim Results from IMPAACT P1066: Raltegravir Oral Chewable Tablet Formulation in Children 6 to 11 Years
Sharon Nachman*1, E Acosta2, P Samson3, H Teppler4, B Homony4, T Fenton3, E Handelsman5, C Worrell6, B Graham7, A Wiznia8, and the 1066 Group
1State Univ of New York at Stony Brook, US; 2Univ of Alabama at Birmingham, US; 3Harvard Sch of Publ Hlth, Boston, MA, US; 4Merck Res Labs, North Wales, PA, US; 5Div of AIDS, NIH, Bethesda, MD, US; 6Natl Inst of Child Hlth and Human Devt, NIH, Bethesda, MD, US; 7Frontier Sci and Tech Res Fndn, Buffalo, NY, US; and 8Jacobi Med Ctr, Bronx, NY, US